Liquidia (LQDA) Q3 2024 earnings summary

Executive summary

• Received FDA tentative approval for YUTREPIA for PAH and PH-ILD, but final approval and launch are delayed until May 2025 due to Tyvaso DPI exclusivity, pending litigation outcomes.

• U.S. Supreme Court denied certiorari, ending litigation on three asserted patents, with only the '327 patent remaining in dispute.

• Expanded partnership with Pharmosa for L606, securing global rights and next-generation nebulizer technology.

• Strengthened balance sheet with $100 million in new capital from equity and financing agreements, ending Q3 with $204.4 million in cash.

• Focused on rare cardiopulmonary diseases, with revenue primarily from Sandoz promotion agreement for treprostinil injection.

Financial highlights

• Q3 2024 revenue was $4.4 million, up from $3.7 million in Q3 2023, mainly from the Sandoz promotion agreement.

• Cost of revenue increased to $1.7 million from $0.6 million year-over-year, reflecting sales force expansion.

• R&D expenses rose 60% to $11.9 million, and G&A expenses nearly doubled to $20.2 million, mainly due to personnel and legal fees.

• Net loss for Q3 2024 was $23.2 million ($0.30/share), compared to $15.8 million ($0.24/share) in Q3 2023.

• Cash and cash equivalents at September 30, 2024 were $204.4 million, up from $83.7 million at year-end 2023.

Outlook and guidance

• YUTREPIA launch planned for 2025, pending final FDA approval and litigation outcome; commercial supply and payer access preparations are in place.

• L606 pivotal global phase III study in PH-ILD to begin in H1 2025, with enrollment expected to take 18–24 months.

• ASCEND study for YUTREPIA in PH-ILD on track to complete enrollment in Q1 2025, with data expected in H1 2025.

• Cash on hand, excluding future YUTREPIA revenue, is expected to fund operations for at least 12 months, but substantial doubt exists if approval is further delayed.

• Additional capital will be required to support operations, product launches, and pipeline development.